Skip navigation

Forward-Looking Statements This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. Words such as plans, believes, expects, anticipates, and will, and similar expressions, are intended to identify forward-looking statements. forward-looking statements include, without limitation, statements regarding: Ligands future revenue growth, including the timing, mix and volume of Captisol orders, the timing of the initiation or completion of clinical trials by Ligand and its partners, the timing of review of clinical data by the FDA, expected value creation for shareholders and guidance regarding the full-year 2016 and 2017 financial results. Actual events or results may differ from Ligand’s expectations. For example, Ligand may not receive expected revenue from material sales of Captisol, expected royalties on other partnered products and research or development milestone payments. Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline. In addition, Ligand’s review of DTA may result in a reduction of DTA greater than currently expected. Any resulting reclassification to the 2015 financial statements may also result in Ligand’s inability to rely on the auditors’ opinion with respect to the 2015 financial statements and the need for a new audit of the 2015 financial statements and amended periodic reports for 2015 and 2016. addition, there can be no assurance that Ligand will achieve its guidance for 2016 or 2017 or any portion thereof or beyond, that Ligand’s 2016 or 2017 revenues will be at the levels as currently anticipated, that Ligand will be able to create future revenues and cash flows by developing innovative therapeutics, that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development by Ligand or its partners will receive regulatory approval, that there will be a market for the product(s) if successfully developed and approved, or that Ligand’s partners will not terminate any of its agreements or development or commercialization of any of its products. Further, Ligand may not generate expected revenues under its existing license agreements and may experience significant costs as the result of potential delays under its supply agreements.

For the original version including any supplementary images or video, visit

Examine the epithelium for abrasions, enema, ulcers, or foreign bodies. The retina is a light-sensitive membrane that lines the back of the eyes and transmits converts light into electrical impulses and transmits them to the optic nerve and the brain. Molecular targets of dietary poly phenols with anti-inflammatory properties. downer BC, Mae R, Becket MD, Heinz C, Veltrup I, Heiligenhaus A, Barisani-Asenbauer T, Mackensen F. Eye care professionals may also describe the disease as infectious or non-infectious uveitis. She currently practices at One to One Eye Care in San Diego, A. More Information on This Topic Reviewed By: Franklin W. Several treatment options are available. Management of the red eye for the primary care physician. The following are treatment options for each type of uveitis: Treatment for anterior uveitis, or iritis, includes dark glasses, eye drops to dilate the pupil and reduce pain, and steroid eye drops to reduce inflammation or irritation. Uveitis can be caused by many kinds of trauma, including a virus, bacteria infections, or parasites. See complications of uveitis for more information. These include needing further surgery and an increased risk of developing cataracts cloudy patches in the lens of the eye. Iritis is usually the least serious type of uveitis.

Leave a Reply

Your email address will not be published. Required fields are marked *